Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Clearmind closes recruitment for repeat-dosing stage of alcohol disorder drug study

The Israel-based company has finished signing up participants for the placebo-controlled third stage of its early-to-mid-stage CMND-100 trial, but has released no data or timelines.

16 Nov 2026 · Clearmind Medicine Inc. CMND · Company news

Clearmind Medicine said on 16 November 2026 that it has finished recruiting for Part C of the Phase I/IIa trial of CMND-100, its oral candidate for alcohol use disorder (AUD). The company describes the molecule as free of hallucinogenic effects and rooted in psychedelic research.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Clearmind Medicine Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →